“South Africa has officially begun rolling out Lenacapavir, a long‑acting HIV prevention injection administered every six months, offering discreet and effective protection. The initiative is expected to significantly reduce new infections and strengthen the country’s goal of ending AIDS as a public health threat by 2030.”
South Africa has taken a historic step in its decades‑long battle against HIV/AIDS with the official rollout of Lenacapavir, a revolutionary HIV prevention injection administered only twice a year. The programme, launched by President Cyril Ramaphosa in Mpumalanga, represents one of the most significant advances in HIV prevention in recent years. With nearly 8 million South Africans living with HIV and a prevalence rate of 18.1% among adults aged 15–49, the stakes could not be higher.
What is Lenacapavir?
- Lenacapavir is a long‑acting antiretroviral drug designed for HIV prevention.
- Unlike oral PrEP, which requires daily adherence, Lenacapavir is administered via injection every six months.
- Its discreet administration reduces stigma, making it particularly appealing to vulnerable groups such as adolescent girls, sex workers, and men who have sex with men.
Why It Matters
- Adherence Challenge: Daily oral PrEP has faced uptake issues due to stigma and forgetfulness.
- Discreet Protection: A twice‑yearly injection allows individuals to protect themselves without drawing attention.
- Global Strategy Alignment: The rollout supports the Global AIDS Strategy 2026–2030, aiming to end AIDS as a public health threat by 2030.
Government’s Rollout Plan
- Phase One: Distribution to 360 public clinics across six provinces.
- Target: Reach 1 million people by 2027 and 3 million within three years.
- First Batch: 37,920 doses arrived in April 2026.
Public Health Impact
- Reduced New Infections: Lenacapavir is expected to drastically cut HIV transmission rates.
- Improved Continuity: Twice‑yearly administration ensures better adherence compared to daily pills.
- Focus on Vulnerable Groups: Adolescents and young women remain disproportionately affected, and Lenacapavir offers a new prevention tool tailored to their needs.
Voices from Civil Society
- Treatment Action Campaign Chairperson Sibongile Tshabalala praised the injection’s discreet nature, noting it will encourage uptake among those who previously avoided PrEP due to stigma.
- SANAC (South African National AIDS Council) welcomed the rollout, calling it a “gamechanger” in prevention efforts.
Challenges Ahead
- Supply Chain: Ensuring consistent availability across rural and urban clinics.
- Awareness Campaigns: Educating communities about the difference between prevention injections and vaccines.
- Equity: Guaranteeing access for marginalized populations who often face barriers in healthcare.
Conclusion
The rollout of Lenacapavir marks a turning point in South Africa’s HIV response. By shifting from daily prevention methods to a twice‑yearly injection, the country is addressing adherence challenges, reducing stigma, and expanding prevention choices. If successful, this initiative could bring South Africa closer to its ambitious goal of zero new HIV infections by 2030, setting a precedent for other nations grappling with high HIV prevalence.
